From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Drug Target Development Proposals Sought for Antimicrobial-Resistant Pathogens

by Global Biodefense Staff
March 27, 2013

Methicillin-resistant Staphylococcus aureus (NIAID)The National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) has announced a new funding effort to support research focused on characterization and validation of novel drug targets for development of new therapeutics against antimicrobial-resistant bacterial pathogens. 

The initiative is designed to capitalize on the numerous potential drug targets identified through basic research on pathogenesis and the immunobiology of infectious diseases. It is recognized that basic researchers often uncover important pathways, molecular associations, or host-pathogen interactions that may represent viable therapeutic targets. 

The effort seeks to stimulate characterization and validation of these potential therapeutic targets for early phase therapeutic discovery and development activities. Of particular interest is the development of innovative and creative assay methods and validation of potential therapeutic targets that have previously been described. 

Projects eligible for support include target development for small molecule inhibitors, therapeutic antibodies and peptides, and adjunctive therapeutics targeting resistance mechanisms that may not perpetuate the spread of resistance. 

Applications should specifically target bacterial pathogens for which the high incidence of disease is driving the spread of resistance and there are limited options for clinical intervention.

NIAID intends to commit $3.5 million in total costs in FY2014 to fund 15 to 20 applications in response to this FOA. Domestic and foreign entities of all types are eligible to apply.

Further details are available under RFA-AI-13-019. The application due date is July 18, 2013.

Image courtesy of Jeff Hageman, CDC

From Our Partners
Tags: AntimicrobialsMRSARequest for Proposals

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC